ClinicalTrials.gg
RecruitingNCT04798651T4MSUpdated Oct 26, 2026

Pathogenicity of B and CD4 T Cell Subsets in Multiple Sclerosis

An interventional study of blood sample and cerebro-spinal fluid in Multiple Sclerosis and Clinically Isolated Syndrome, sponsored by University Hospital, Bordeaux. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by University Hospital, Bordeaux · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started Sep 2021; still recruiting 5 years 1 month later.
Updated Oct 26, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
150
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 17 studies in Multiple Sclerosis by University Hospital, Bordeaux — 3 open to participants now, 3 under way, none of them phase 3. Multiple Sclerosis · University Hospital, Bordeaux.

Planned enrollment
3rd of 13
150 · median 65
Started
2021
with 1 other
No phase
11 of 17
3 open now
Registered
11th of 17
by date

Among the 17 studies in Multiple Sclerosis by University Hospital, Bordeaux, this one is the 3rd largest by planned enrollment of the 13 interventional ones that give a count, is one of 2 that started in 2021, is one of 11 with no phase, and was the 11th registered.

Multiple Sclerosis

3,273 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

3 of the 17 studies in Multiple Sclerosis by University Hospital, Bordeaux are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 434 Multiple Sclerosis studies recruiting now, 164 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 95 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Multiple Sclerosis by University Hospital, Bordeaux, or all of them as a file.
02

Study summary

The study aims at identifying the type of B and CD4 T cell subsets with pathogenic properties in the different clinical forms of multiple sclerosis. This research might open new therapeutic approaches for the treatment of multiple sclerosis particularly progressive MS.

Read the detailed description

Multiple sclerosis (MS) is a chronic autoimmune disease damaging the central nervous system (CNS). MS is categorized into several distinct forms according to clinical symptoms and medical examinations. Relapsing-remitting multiple sclerosis (RRMS) is characterized by attacks of worsening neurologic function, followed by partial or complete recovery periods. Patients can also present a gradual but steady progression of the disease (progressive forms). While several treatment options are currently available, no treatment completely stops the disease progression. Therefore, a deeper understanding regarding the mechanism of the disease development is essential to generate more efficient treatment strategies. CD4 T cells are known to be significantly involved in the formation of the CNS lesions characteristic of MS.The investigators hypothesize that different types of B and CD4 T cells play major roles in different forms of the disease. They will determine the phenotype and functions of the cells from the immune system particularly B and CD4 T cells present in the blood and cerebro-spinal fluid (CSF) of patients diagnosed with multiple sclerosis or presenting a clinically isolated syndrome.

The study will recruit 150 patients followed in Bordeaux University Hospital and diagnosed for clinically isolated syndrome (CIS) or multiple sclerosis (MS). Blood and CSF will be collected during a scheduled visit to study the properties of cells from the immune system in particular CD4 T cells in multiple sclerosis. Clinical and biological disease activity, treatment and outcomes will be studied in correlation with the properties of blood and CSF lymphocytes. No extra visit will be needed and the blood and CSF samples will be collected at the same times as those collected for clinical purposes.

03

Conditions studied

  • Multiple Sclerosis
  • Clinically Isolated Syndrome

Keywords

  • Autoimmune Diseases of the Nervous System
  • Multiple sclerosis
  • clinically isolated syndrome
  • lymphoid cells
  • CD4 T cells
  • B cells
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • male or female subjects ;
  • Age ≥ 18 years;
  • subjects with MS defined by 2010 revised McDonald criteria or presenting a clinical isolated syndrome;
  • patients for which a blood draw and / or lumbar puncture to collect CSF is performed for diagnostic or therapeutic purpose;
  • affiliated to an health insurance system;
  • and who agree to participate in the study.

Exclusion criteria

Exclusion Criteria:

  • Pregnant or breastfeeding women,
  • patient concerned by articles L 1121-5 to L 1121-8 (persons deprived of their liberty by a judicial or administrative decision, minors, persons of legal age who are the object of a legal protection measure or unable to express their consent)
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    patients with multiple sclerosis or clinically isolated syndrome

    subjects with MS defined by 2010 revised McDonald criteria or presenting a clinical isolated syndrome

    Biological: blood sample · Biological: cerebro-spinal fluid

Interventions

  • Biologicalblood sample

    28 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation

  • Biologicalcerebro-spinal fluid

    1 ml of cerebro-spinal fluid

06

What researchers measure

Primary outcomes

  1. Functional and phenotypical characterization of the blood and CSF lymphocytes in MS and CIS patients.

    Time frame: At inclusion (day 0)

Secondary outcomes

  1. Quantification of disease activity scores

    Expanded Disability Status Scale (EDSS)

    Time frame: At inclusion (day 0)

  2. Quantification of disease activity scores

    ambulation test

    Time frame: At inclusion (day 0)

  3. Number of lesions

    evaluated by MRI

    Time frame: At inclusion (day 0)

  4. Size of lesions

    evaluated by MRI

    Time frame: At inclusion (day 0)

  5. Localisation of lesions

    evaluated by MRI

    Time frame: At inclusion (day 0)

  6. Types of lesions

    evaluated by MRI

    Time frame: At inclusion (day 0)

  7. duration of the disease

    Time frame: At inclusion (day 0)

  8. age at onset and progression

    Time frame: At inclusion (day 0)

  9. number of relapses

    Time frame: At inclusion (day 0)

  10. date of relapses

    Time frame: At inclusion (day 0)

  11. Treatment

    Time frame: At inclusion (day 0)

07

Study locations

1 of 1 sites recruiting
  • CHU de Bordeaux - service de neurologie
    Bordeaux, France
    Recruiting
    • Aurélie RUET, Prof · Contactaurelie.ruet@chu-bordeaux.fr
    • Aurélie RUET, Prof · Principal investigator
    • Jean-Christophe OUALLET, MD · Sub investigator
    • Pauline BUISSONNIERE, MD · Sub investigator
    • Louis NADAL, MD · Sub investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2021 (actual). Primary completion is estimated for Sep 2027, 72 months after the start.

Of 852 non-industry interventional studies with no phase under Multiple Sclerosis, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 43. This study's planned 72 months is above that.

Counting every sponsor, half of 874 studies reached it within 21 months; a quarter within 9 and three quarters within 43.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 26, 2026: primary completion Sep 2026 → Sep 2027 and completion Sep 2026 → Sep 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 11, 2021
First posted
Mar 15, 2021
StartActual
Sep 30, 2021
Primary completionEst.
Sep 2027was Sep 2026
CompletionEst.
Sep 2027was Sep 2026
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Sep 2026→Sep 2027
Oct 26, 2026
Study completion
Sep 2026→Sep 2027
Oct 26, 2026
Show all 1 update
  1. Oct 26, 2026
    Primary completion Sep 2026→Sep 2027
    Study completion Sep 2026→Sep 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04798651
Collaborators
University of Bordeaux
Responsible party
Sponsor
First posted
Mar 15, 2021
Start date
Sep 30, 2021
Primary completion
Sep 2027 (estimated)
Completion
Sep 2027 (estimated)
Last update
Oct 26, 2026

Study contacts

Aurélie RUET, Prof
Contact
aurelie.ruet@chu-bordeaux.fr
05 56 79 55 21 ext. +33
Aurélie RUET, Prof
principal investigator · University Hospital, Bordeaux
Nathalie SCHMITT, PhD
study director · University of Bordeaux

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion